HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valeant Builds Outside Of Dermatology With Bausch + Lomb Buy

This article was originally published in The Rose Sheet

Executive Summary

Acquisition of Bausch + Lomb for $8.7 billion vaults Valeant Pharmaceuticals into consumer eye care and positions the firm to compete against pharma giants. Analysts see the move as representing “a good fit,” and the acquisition is not likely to be the last for Valeant, which has made M&A an integral part of its strategy.

You may also be interested in...



In Brief

FDA invites public input in preparation for the seventh meeting of national authorities under the International Cooperation on Cosmetics Regulation, while The National Toxicology Program requests information on technologies and non-animal approaches that can be used to screen compounds for potential neurotoxicity. More news in brief.

AcneFree Purchase Builds U.S. Scale For Canadian Dermatology Firm

The addition of AcneFree to Valeant Pharma’s OTC portfolio will complement the Montreal firm’s CeraVe skin hydration line and augment its shelf space in U.S. retail doors. Valeant announced $64 million purchase from University Medical earlier this month.

People In Brief

Herbalife brings on Dentali as botanical sciences VP; NACDS expands Nicholson’s role; Innophos announces interim CFO; George Hamilton new face of Infusion Life Sciences; Aker BioMarine names sales VP; Atteryd to chair Food Supplements Europe.

Related Companies

UsernamePublicRestriction

Register

RS018563

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel